Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact

被引:134
|
作者
Collins, BE
Blixt, O
DeSieno, AR
Bovin, N
Marth, JD
Paulson, JC
机构
[1] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA
[2] MM Shemyakin Inst Bioorgan Chem, Moscow 117997, Russia
[3] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA
关键词
D O I
10.1073/pnas.0400851101
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CD22, a negative regulator of B cell signaling, is a member of the siglec family that binds to alpha2-6-linked sialic acids on glycoproteins. Previous reports demonstrated that binding of multivalent sialoside probes to CD22 is blocked, or "masked," by endogenous (cis) ligands, unless they are first destroyed by sialidase treatment. These results suggest that cis ligands on B cells make CD22 functionally unavailable for binding to ligands in trans. Through immunofluorescence microscopy, however, we observed that CD22 on resting B cells redistributes to the site of contact with other B or T lymphocytes. Redistribution is mediated by interaction with trans ligands on the opposing cell because it does not occur with ligand-deficient lymphocytes from ST6Gall-null mice. Surprisingly, CD45, proposed as both a cis and trans ligand of CD22, was not required for redistribution to sites of cell contact, given that redistribution of CD22 was independent of CD45 and was observed with lymphocytes from CD45-deficient mice. Furthermore, CD45 is not required for CD22 masking as similar levels of masking were observed in the WT and null mice. Comparison of the widely used sialoside-polyacrylamide probe with a sialoside-streptavidin probe revealed that the latter bound a subset of B cells without sialidase treatment, suggesting that cis ligands differentially impacted the binding of these two probes in trans. The combined results suggest that equilibrium binding to cis ligands does not preclude binding of CD22 to ligands in trans, and allows for its redistribution to sites of contact between lymphocytes.
引用
收藏
页码:6104 / 6109
页数:6
相关论文
共 50 条
  • [31] Identification of the gene variations in human CD22
    Hatta, Y
    Tsuchiya, N
    Matsushita, M
    Shiota, M
    Hagiwara, K
    Tokunaga, K
    IMMUNOGENETICS, 1999, 49 (04) : 280 - 286
  • [32] Identification of the gene variations in human CD22
    Yoko Hatta
    N. Tsuchiya
    Masaki Matsushita
    Michiko Shiota
    Kiyofumi Hagiwara
    Katsushi Tokunaga
    Immunogenetics, 1999, 49 : 280 - 286
  • [33] Generation of a Highly Sensitive CD22 CAR
    Kokalaki, Evangelia K.
    Ma, Biao
    Grothier, Thomas
    Hazelton, Warren
    Costu, Eren
    Manzoor, Somayya
    Jha, Ram
    Thomas, Simon
    Onuoha, Shimobi
    Cordoba, Shaun P.
    Pule, Martin
    BLOOD, 2019, 134
  • [34] Targeting CD22 for B-cell hematologic malignancies
    Jia Xu
    Wenjing Luo
    Chenggong Li
    Heng Mei
    Experimental Hematology & Oncology, 12
  • [35] Understanding the role of CD22 on Macrophage and Dendritic Cell Function
    Zastrow, Alexi
    Friedman, David J.
    Crotts, Sydney B.
    Rajcula, Matthew
    Hammer, Brady
    Elissa, Mai
    Shapiro, Virginia Smith
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01)
  • [36] ASSOCIATION OF CD22 WITH THE B-CELL ANTIGEN RECEPTOR
    PEAKER, CJG
    NEUBERGER, MS
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (06) : 1358 - 1363
  • [37] Soluble CD22 as a tumor marker for hairy cell leukemia
    Matsushita, Kakushi
    Margulies, Inger
    Onda, Masanori
    Nagata, Satoshi
    Stetler-Stevenson, Maryalice
    Kreitman, Robert J.
    BLOOD, 2008, 112 (06) : 2272 - 2277
  • [38] Human CD22 cannot fully substitute murine CD22 functions in vivo, as shown in a new knockin mouse model
    Woehner, Miriam
    Born, Stefanie
    Nitschke, Lars
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (11) : 3009 - 3018
  • [39] Sialoside regulation of B cell function through CD22
    Collins, BE
    Nitschke, L
    Marth, JD
    Paulson, JC
    GLYCOBIOLOGY, 2003, 13 (11) : 884 - 884
  • [40] Targeting CD22 for the Treatment of B-Cell Malignancies
    Shah, Nikesh N.
    Sokol, Lubomir
    IMMUNOTARGETS AND THERAPY, 2021, 10 : 225 - 236